drugset / Trial / NCT00926055

Effects on Atherosclerosis Regression of Ezetimibe or Ezetimibe Plus Simvastatin; Evaluated by Fluorodeoxyglucose Positron Emission Tomography (FDG-PET)

NCT00926055

Withdrawn Korea University
RandomizedParallel-groupQuadruple-blindTreatment

Summary

18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) is a promising tool for identifying and quantifying vascular inflammation within atherosclerotic plaques. Therefore, in this study the investigators intend to compare the effect of ezetimibe monotherapy or ezetimibe plus statin combination therapy on the atherosclerosis regression using FDG-PET.

Timeline

Start
2011-09
Primary completion
2012-09
Completion

Drugs

EvaluationDrugModalityDoseRoute
Comparator Ezetimibe Unknown 10 mg
Subject Simvastatin Small molecule 20 mg

Indications